- Home
- GBLI vs PALI Comparison
GBLI vs PALI Comparison
Compare GBLI & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GBLI | PALI |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.7M | 359.7M |
| IPO Year | 2010 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GBLI | PALI |
|---|---|---|
| Price | $30.00 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.29 |
| AVG Volume (30 Days) | 3.8K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ 1.05 | N/A |
| Revenue | ★ $450,098,000.00 | $260,000.00 |
| Revenue This Year | $14.23 | N/A |
| Revenue Next Year | $9.68 | N/A |
| P/E Ratio | $28.57 | ★ N/A |
| Revenue Growth | 2.02 | ★ 1500.39 |
| 52 Week Low | $24.28 | $0.55 |
| 52 Week High | $30.20 | $2.86 |
Technical Indicators
Market Signals| Indicator | GBLI | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 63.31 | 48.11 |
| Support Level | $27.56 | $1.81 |
| Resistance Level | N/A | $2.18 |
| Average True Range (ATR) | 1.20 | 0.09 |
| MACD | 0.22 | -0.02 |
| Stochastic Oscillator | 98.39 | 29.51 |
Price Performance
Historical ComparisonAbout GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.